Aurora Therapeutics launched with seed funding and a leadership team tied to the ‘Baby KJ’ personalized CRISPR success story, aiming to develop grouped, customizable gene‑editing therapies that can be adjusted for multiple mutations without full repeat trials. The company, backed by Menlo Ventures and affiliated seed investors, will initially target phenylketonuria (PKU) and intends to pursue regulatory strategies available through the FDA’s emerging ‘plausible mechanism’ or bespoke therapy frameworks. Aurora’s model seeks to aggregate multiple variant corrections under umbrella filings to improve economic feasibility for ultra‑rare and private‑mutation indications. The startup said it has preclinical proof‑of‑concept and early regulatory interactions to support a grouped development path.